Cargando…
Cell death in response to antimetabolites directed at ribonucleotide reductase and thymidylate synthase
New agent development, mechanistic understanding, and combinatorial partnerships with known and novel modalities continue to be important in the study of pancreatic cancer and its improved treatment. In this study, known antimetabolite drugs such as gemcitabine (ribonucleotide reductase inhibitor) a...
Autores principales: | Asuncion Valenzuela, Malyn M, Castro, Imilce, Gonda, Amber, Diaz Osterman, Carlos J, Jutzy, Jessica M, Aspe, Jonathan R, Khan, Salma, Neidigh, Jonathan W, Wall, Nathan R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354452/ https://www.ncbi.nlm.nih.gov/pubmed/25767396 http://dx.doi.org/10.2147/OTT.S79647 |
Ejemplares similares
-
Antimetabolite Treatment for Pancreatic Cancer
por: Valenzuela, Malyn May Asuncion, et al.
Publicado: (2014) -
Modulation of the Ribonucleotide Reductase-Antimetabolite Drug Interaction in Cancer Cell Lines
por: Zhou, Jun, et al.
Publicado: (2010) -
Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion
por: Mannava, Sudha, et al.
Publicado: (2012) -
Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer
por: Khan, Salma, et al.
Publicado: (2012) -
Enhancement of Gemcitabine sensitivity in pancreatic adenocarcinoma by novel exosome-mediated delivery of the Survivin-T34A mutant
por: Aspe, Jonathan R., et al.
Publicado: (2014)